Alexandria Real Estate Equities Inc当前公司基本面数据相对健康,最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理,在住宅与商业类房地产信托基金(REIT)行业排名83/191位。机构持股占比非常高,近一月多位分析师给出公司评级为持有。最高目标价65.07。中期看,股价处于平稳状态。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
Alexandria Real Estate Equities Inc评分
相关信息
行业排名
83 / 191
全市场排名
160 / 4521
所属行业
住宅与商业类房地产信托基金(REIT)
压力支撑
由于公司未披露,未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
2°C
过冷
过热
看好
Alexandria Real Estate Equities Inc亮点
亮点风险
Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry.
Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry.